Molecular Cancer Research publishes articles featuring novel, basic cancer research discoveries that prioritize broad molecular and cellular processes. Areas of emphasis include cell cycle and ...
Search for other works by this author on: ...
Search for other works by this author on: ...
University of Nebraska Medical Center, Omaha, NE, ...
Adding the PD-1 inhibitor pembrolizumab to chemoradiotherapy for high-risk, locally advanced cervical cancer significantly improves patients’ overall survival compared to treatment with CRT alone.
Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...
Copyright held by the owner/author(s).
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
According to data presented at the ESMO Congress 2024, being held from September 13–17 in Barcelona, Spain, for patients with advanced renal cell carcinoma, oncologists should avoid prescribing ...
Two HER2-targeted tyrosine kinase inhibitors, BAY 29270078 and zongertinib, each showed robust efficacy and safety in early phase. Patients experienced significant tumor shrinkage rates, and the ...
Search for other works by this author on: ...